Taylor & Francis Group
Browse

File(s) not publicly available

Co(III), Ni(II) and Cu(II) complexes with a tetradentate Schiff base ligand: synthesis, characterization, electrochemical behavior, binding assessment and in vitro cytotoxicity

Version 2 2022-05-09, 16:40
Version 1 2022-01-31, 17:20
online resource
posted on 2022-05-09, 16:40 authored by Marija Mirković, Magdalena Radović, Dalibor Stanković, Sanja Vranješ-Đurić, Drina Janković, Djordje Petrović, Ljiljana E. Mihajlović-Lalić, Željko Prijović, Zorana Milanović

Two new Schiff base cobalt(III) ([Co(LH)Cl2], 1) and nickel(II) ([Ni(LH)ClO4], 2) complexes with a diimine-dioxime ligand, (4,9-diaza-3,10-diethyl-3,9-dodecadiene-2,11-dione bis oxime (LH2)), were synthesized and characterized. The compounds were obtained in MeOH from corresponding metal salts and LH2 in molar ratio 1:1 and further characterized by mass spectrometry, IR spectroscopy, electrochemistry, and elemental analysis. Previously reported copper(II) analog ([Cu2(LH)2]·(ClO4)2, 3) was joined to 1 and 2, and the three metal analogs, 13, were further investigated in terms of their electrochemical behavior. Binding studies of the complexes with deoxyribonucleic acid (DNA) and human serum albumin (HSA) were carried out using both spectrophotometric and electrochemical methods. All three complexes exhibit binding affinity towards the DNA chain through intercalative interactions. The binding reaction with HSA showed for 1 and 3 decrease in the peak current obtained in the case of complexes before the addition of HSA, while the Ni complex–HSA possesses the same electroactivity as starting complex. The cytotoxicity of LH2 as well as its metal complexes, and cisplatin were evaluated on CT-26 mouse colon carcinoma and human LS174T cancer cell lines employing MTT assay. The copper(II) complex exhibited very promising anticancer activity compared with cisplatin.

Funding

The research was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, contract numbers: 451-03-9/2021-14/200168, 451-03-9/2021-14/200288, 451-03-9/2021-14/200017 and through funding the VINCENT Center of Excellence, and through EUREKA project E! 13303 MED-BIO-TEST.

History